Aquestive Therapeutics News - August 11, 2026
Aquestive Therapeutics second quarter 2026 revenue of $13.8M missed estimates as Anaphylm resubmission remains on track
Aquestive Therapeutics reported second quarter 2026 revenue of $13.8 million, representing a 38% increase year-over-year but falling short of the $14.2 million...
🟢 Aquestive Therapeutics is trading 7.22% up today after positive Anaphylm results support FDA resubmission
Aquestive Therapeutics is trading 7.22% up now at $4.60 after positive Anaphylm human-factors and pharmacokinetic results supported its planned third-quarter...
🟢 Aquestive Therapeutics is trading 5.59% up in pre-market after positive Anaphylm results support planned FDA resubmission
Aquestive Therapeutics is trading 5.59% up now at $4.53 after positive Anaphylm human-factors and pharmacokinetic results supported a planned third-quarter...